| Formulary Chapter 26: A5 - Wound management products and elasticated garments - Full Chapter
|
| A5.03.03 |
Low adherence dressings |
|
|
Atrauman Ag®
|
Formulary
|
Non adherent Primary Dressing containing metallic silver
Type of wound product is suitable for
For clinically infected shallow, granulating wounds with low exudate. To be used as a primary dressing with a secondary for absorption.
Duration dressing remains on wound before changing
Up to 7 days
Frequency of dressing change
1-7 days, depending on levels of exudate
Caution/contraindications (when not to use the dressing, patient groups to avoid etc.)
Known product or component sensitivity
Must be removed prior to x-ray, ultrasound, diathermy and MRI
Rationale for inclusion in formulary
Used to reduce adherence to wound bed with clinical signs of infection
Most cost effective non adherent dressing containing silver.
Dressing impregnated with neutral triglycerides to prevent penetration of granulation tissue.
Petroleum free.
Specialist Recommendation
|
| A5.03.03 |
Soft polymer dressings |
|
|
| A5.03.03 |
Hydrocolloid dressings |
|
|
| A5.03.03 |
Alginate dressings |
|
|
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Prescribing in children
The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.
The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.
|
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications. |
|
Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements. |
|
Medicines for initiation and maintenance prescribing by Specialists only |
|
Non-formulary medicines- medicines not recommended for routine primary care prescribing. |
|
Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information. |
|
|
